In the present study, therefore, we compare five candidate promoters (for Cox-2, EGP-2, SLPI, survivin and CXCR4) for specific transcriptional control in breast cancer, which might hold promise in the context of future gene therapy or virotherapy regimes for this disease. This evidence concerns the gene SLPI and breast carcinoma.